Anti-CD22/ SIGLEC-2/ SIGLEC2 monoclonal antibody

Anti-CD22/ SIGLEC-2/ SIGLEC2 antibody for FACS & in-vivo assay

Target products collectionGo to CD22/CD22 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T37539-Ab-1/ GM-Tg-hg-T37539-Ab-2Anti-Human CD22 monoclonal antibodyHuman
GM-Tg-rg-T37539-Ab-1/ GM-Tg-rg-T37539-Ab-2Anti-Rat CD22 monoclonal antibodyRat
GM-Tg-mg-T37539-Ab-1/ GM-Tg-mg-T37539-Ab-2Anti-Mouse CD22 monoclonal antibodyMouse
GM-Tg-cynog-T37539-Ab-1/ GM-Tg-cynog-T37539-Ab-2Anti-Cynomolgus/ Rhesus macaque CD22 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T37539-Ab-1/ GM-Tg-felg-T37539-Ab-2Anti-Feline CD22 monoclonal antibodyFeline
GM-Tg-cang-T37539-Ab-1/ GM-Tg-cang-T37539-Ab-2Anti-Canine CD22 monoclonal antibodyCanine
GM-Tg-bovg-T37539-Ab-1/ GM-Tg-bovg-T37539-Ab-2Anti-Bovine CD22 monoclonal antibodyBovine
GM-Tg-equg-T37539-Ab-1/ GM-Tg-equg-T37539-Ab-2Anti-Equine CD22 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T37539-Ab-1/ GM-Tg-hg-T37539-Ab-2; GM-Tg-rg-T37539-Ab-1/ GM-Tg-rg-T37539-Ab-2;
GM-Tg-mg-T37539-Ab-1/ GM-Tg-mg-T37539-Ab-2; GM-Tg-cynog-T37539-Ab-1/ GM-Tg-cynog-T37539-Ab-2;
GM-Tg-felg-T37539-Ab-1/ GM-Tg-felg-T37539-Ab-2; GM-Tg-cang-T37539-Ab-1/ GM-Tg-cang-T37539-Ab-2;
GM-Tg-bovg-T37539-Ab-1/ GM-Tg-bovg-T37539-Ab-2; GM-Tg-equg-T37539-Ab-1/ GM-Tg-equg-T37539-Ab-2
Products NameAnti-CD22 monoclonal antibody
Formatmab
Target NameCD22
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD22 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-358Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
    BiosimilarGMP-Bios-INN-868Pre-Made Inotuzumab Ozogamicin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-275Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
    BiosimilarGMP-Bios-INN-960Pre-Made Pinatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-190Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
    BiosimilarGMP-Bios-INN-751Pre-Made Bectumomab Biosimilar, Fab Fusion, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody
    BiosimilarGMP-Bios-ab-444Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
    BiosimilarGMP-Bios-ab-697Pre-Made Suciraslimab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
    BiosimilarGMP-Bios-INN-920Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A
    Target AntigenProducts DevelopingMulti-species CD22/ SIGLEC-2/ SIGLEC2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T37539
    Target NameCD22
    Gene ID933,12483,308501,106994739,476485,101081100,514582,100146402
    Gene Symbol and SynonymsA530093D23,CD22,Lyb-8,Lyb8,SIGLEC-2,SIGLEC2
    Uniprot AccessionP20273
    Uniprot Entry NameCD22_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseCancer
    Gene EnsemblENSG00000012124
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: CD22, gene name: CD22, also named as SIGLEC-2, SIGLEC2. Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.